Instead when the two immunoagents are administered separately, the bi-specific construct binds to tumor cells with one arm and T cells with the other arm whereas the anti-IC mAb could bind to other cell populations such as tumor-associated macrophages, fibroblasts, mast cells, B cells, and T cells within solid tumors that may become PD-L1+ in response to IFNγ. The gene discussed is CD274; the disease is neoplasm.